UBS maintains Buy on BMY ahead of Ph3 IPF review
UBS says a deep dive into BMY’s Phase 3 IPF studies is coming up and keeps a Buy rating with an $80 price target.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.